Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO
The data reflects our commitment to strengthening our oncology pipeline across immuno-oncology, synthetic lethality & oncology cell therapy
-
GSK Consumer Healthcare leads oral care industry with launch of its first carbon neutral toothbrush
73% of consumers say they would definitely change their consumption habits to reduce their environmental impact.
-
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data
-
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours
GARNET study demonstrated objective response rate of 41.6% across dMMR solid tumours
-
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone
-
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
Fourth indication for mepolizumab in the US for eosinophil-driven diseases.
-
GSK delivers strong Q2 sales of £8.1 billion, +6% AER, +15% CER Total EPS 27.9p -39% AER, -28% CER; Adjusted EPS 28.1p +46% AER +71% CER
Sales growth driven by strong commercial execution and favourable prior year comparison
-
GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab
GlaxoSmithKline plc and Vir Biotechnology, Inc. announce the supply of 220,000 doses of sotrovimab for adults and adolescents with COVID-19.
-
Shingrix approved in the US for prevention of shingles in immunocompromised adults
Immunocompromised individuals are at greater risk of shingles and associated complications than immunocompetent individuals
-
Brian McNamara appointed CEO Designate of new independent Consumer Healthcare company
Brian McNamara, the CEO of GSK Consumer Healthcare, has been appointed as CEO Designate of the new Consumer Healthcare company.
-
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
ViiV Healthcare today presented 48-week data from the SALSA study at the International AIDS Society Conference 2021
-
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
ViiV Healthcare today presented positive findings from the CUSTOMIZE trial
-
ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021
Data to be presented underscore the commitment to developing innovative treatment and prevention options
-
GSK announces positive headline results from five Phase 3 studies of daprodustat for patients with anaemia due to chronic kidney disease
Full results to be presented at a medical meeting later this year
-
GSK unveils plan for one of Europe’s largest life science campuses in Stevenage
Plan aims to unlock up to £400 million of new private investment and create up to 5,000 new highly-skilled jobs over next decade.
-
New study shows more needs to be done to raise public awareness on the impact of good oral health habits on overall health
A new study by Ipsos and GSK Consumer Healthcare reveals the need to improve public awareness of the benefits of good oral health.
-
GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases
-
Elliott Advisors (UK) letter to GSK
The Board of GSK notes the letter issued by Elliott Advisors (UK) Limited (“Elliott”) on 1 July
-
New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline
New GSK to positively impact health of >2.5 billion people next 10 years
-
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
Halozyme’s technology provides more “shots on goal” to create ultra long-acting HIV medicines with dosing intervals of 3 months or longer
